



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 15 Jul 2019 (#23)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- [Clarifying Long-Standing NIH Policies on Disclosing Other Support](#) - Institutions and investigators must disclose all forms of what is termed “other support” when applying for and receiving NIH grants. Other support includes all resources, regardless of whether or not they have monetary value, available in direct support of an individual’s research endeavors
- **Tips Before You Submit: Project Summary/Abstract and a Project Narrative**, two sections that, if the application is funded, are made available on RePORTER to help the public understand the value of NIH-funded research. [What’s the difference and what to Include in these documents](#)
- Wondering where to go for information on NIH’s Human Subjects Inclusion policies? Visit the new [Inclusion Policies for Research Involving Human Subjects](#) page where you can navigate to learn more about NIH policies on [the inclusion of women and minorities](#) and the [inclusion of individuals across the lifespan](#).
- [NOT-OD-19-114](#): Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components
- [NOT-TW-19-005](#): Notice of FIC Intent to Publish a Funding Opportunity Announcement for HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions.

1. Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-311](#)

Type: R21/R33

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).

Budget: For the R21 phase, the combined budget for direct costs during the two-year project period may not exceed \$275,000 with no more than \$200,000 requested in a single year. For the R33 phase, the direct costs should not exceed \$500,000 per year. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

2. Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-315](#)

Type: R61/R33

Application Due Date: September 4, 2019; February 14, 2020; July 20, 2020 and **AIDS dates:** September 7, 2019; May 7, 2020; September 7, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The R61 phase can be from 1-3 years and the R33 phase can be 1-2 years, with a total project duration of no more than 5 years

3. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R01 - Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-20-006](#)

Type: R01

Application Due Date: November 14, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

Budget: NIDA intends to commit \$1M in FY2020 to fund 3-5 awards from this R01 and the R21. Future year amounts will depend on annual appropriations. Application budgets are limited to direct costs of \$350k. Project periods cannot exceed 5 years.

4. Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-20-023](#)

Type: R01

Application Due Date: November 12, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines.

Budget: NIH intends to fund an estimate of three to five awards, corresponding to a total of \$2,000,000, for fiscal year 2020. Future year amounts will depend on annual appropriations. Application budgets are limited to no more than \$500,000 direct cost. The maximum project period is 5 years.

5. Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)

Letter of Intent: 60 days prior to the application due date. Please note, although LOIs are typically due 30 days before the due date, for this FOA LOIs are due 60 days prior to the application date.

Hyperlink: [RFA-OD-19-021](#)

Type: R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.

The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

Budget: NIH, via support from the FDA Center for Tobacco products (CTP), intends to fund up to 7 R21s, corresponding to a total of up to \$1.5 million, for fiscal year 2020. Future year amounts will depend on availability of funds. The combined budget for direct costs for the entire project period may not exceed \$275,000. No more than \$200,000 in direct cost may be requested in any single year. The maximum project period is 2 years.

6. Secondary Analyses of Existing Datasets of Tobacco Use and Health (Clinical Trial Not Allowed)

Letter of Intent: 60 days prior to the application due date. Please note, although LOIs are typically due 30 days before the due date, for this FOA LOIs are due 60 days prior to the application date.

Hyperlink: [RFA-OD-19-022](#)

Type: R21

Application Due Date: October 8, 2019, July 20, 2020, March 8, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

Budget: The number of awards is contingent upon funding availability, submission of a sufficient number of meritorious applications, and programmatic priority. NIH, via support from the FDA Center for Tobacco products (CTP), intends to fund up to 5 R21s, corresponding to a total of \$1.0 million for fiscal year 2020. Future year amounts will depend on availability of funds. The combined budget for direct costs for the entire project period may not exceed \$275,000. No more than \$200,000 in direct cost may be requested in any single year. The maximum project period is 2 years

7. Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-19-011](#)

Type: R03

Application Due Date: October 28, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; <https://commonfund.nih.gov/idg/index>) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG's Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins. The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.

Budget: The NIH Common Fund intends to commit approximately \$1,750,000 in FY 2020, contingent upon receiving scientifically meritorious applications. 9-11 awards are anticipated from this solicitation. Application budgets are limited to \$100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for an application submitted under this FOA is 1 year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105